Mind Medicine Inc
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials… Read more
Mind Medicine Inc (MNMD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.226x
Based on the latest financial reports, Mind Medicine Inc (MNMD) has a cash flow conversion efficiency ratio of -0.226x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.57 Million) by net assets ($130.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mind Medicine Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Mind Medicine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mind Medicine Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mind Medicine Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
0.066x |
|
Youngy Co Ltd
SHE:002192
|
0.015x |
|
Sichuan Tuopai Shede Wine Co Ltd
SHG:600702
|
-0.042x |
|
Sineng Electric Co Ltd
SHE:300827
|
-0.050x |
|
FRANKS INTL N.V. EO -01
F:FK2
|
0.042x |
|
Asmedia Technology Inc
TW:5269
|
0.060x |
|
Torm PLC Class A
NASDAQ:TRMD
|
0.053x |
|
Nanjing ESTUN Automation Co Ltd
SHE:002747
|
0.208x |
Annual Cash Flow Conversion Efficiency for Mind Medicine Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Mind Medicine Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $241.45 Million | $-79.13 Million | -0.328x | +60.22% |
| 2023-12-31 | $78.13 Million | $-64.36 Million | -0.824x | -147.95% |
| 2022-12-31 | $150.92 Million | $-50.14 Million | -0.332x | -9.96% |
| 2021-12-31 | $151.66 Million | $-45.82 Million | -0.302x | +2.86% |
| 2020-12-31 | $75.87 Million | $-23.60 Million | -0.311x | -309.18% |
| 2019-12-31 | $2.74 Million | $-208.12K | -0.076x | +62.91% |
| 2018-12-31 | $3.52 Million | $-722.45K | -0.205x | -21.47% |
| 2017-12-31 | $3.95 Million | $-665.98K | -0.169x | +19.37% |
| 2016-12-31 | $127.28K | $-26.64K | -0.209x | -27.73% |
| 2015-12-31 | $284.17K | $-46.56K | -0.164x | -- |